down arrow

Vicore Pharma Holding AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0007577895
SEK
10.36
0.5 (5.07%)

Dec 04

OME

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Swedish Orphan Biovitrum AB
Camurus AB
BioArctic AB
Swedencare AB
Calliditas Therapeutics AB
Egetis Therapeutics AB
Hansa Biopharma AB
Vicore Pharma Holding AB
Xspray Pharma AB
Infant Bacterial Therapeutics AB
FluoGuide A/S
Why is Vicore Pharma Holding AB ?
1
  • NET SALES(HY) At SEK 6 MM has Grown at -94.25%
  • PRE-TAX PROFIT(Q) Lowest at SEK -111.53 MM
  • NET PROFIT(Q) Lowest at SEK -111.53 MM
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 37.58%, its profits have fallen by -85.4%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vicore Pharma Holding AB for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Vicore Pharma Holding AB
37.58%
-0.97
54.96%
OMX Stockholm 30
8.01%
0.44
18.11%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
56.87%
EBIT Growth (5y)
-201.69%
EBIT to Interest (avg)
-94.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.12
Tax Ratio
0.05%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.85
EV to EBIT
-4.61
EV to EBITDA
-4.62
EV to Capital Employed
-57.37
EV to Sales
212.95
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-40.84%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
NET PROFIT(HY)

Higher at SEK -195.61 MM

ROCE(HY)

Highest at -41.33%

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

CASH AND EQV(HY)

Highest at SEK 2,204.76 MM

-33What is not working for the Company
NET SALES(HY)

At SEK 6 MM has Grown at -94.25%

PRE-TAX PROFIT(Q)

Lowest at SEK -111.53 MM

NET PROFIT(Q)

Lowest at SEK -111.53 MM

INTEREST(Q)

Highest at SEK 26.41 MM

Here's what is working for Vicore Pharma Holding AB
Cash and Eqv
Highest at SEK 2,204.76 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Vicore Pharma Holding AB
Net Sales
At SEK 6 MM has Grown at -94.25%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (SEK MM)

Pre-Tax Profit
At SEK -111.53 MM has Fallen at -452.75%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (SEK MM)

Net Profit
At SEK -111.53 MM has Fallen at -451.68%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (SEK MM)

Interest
At SEK 26.41 MM has Grown at 2,640,400%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Pre-Tax Profit
Lowest at SEK -111.53 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (SEK MM)

Net Profit
Lowest at SEK -111.53 MM and Fallen
In each period in the last five periods
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (SEK MM)

Interest
Highest at SEK 26.41 MM
in the last five periods and Increased by 2,640,400% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."